Last reviewed · How we verify
NCT06837324: brain disorder
Effect of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder
NA trial testing home-based Neofect Smart Glove in Brain Disorder in 40 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 11 April 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- home-based Neofect Smart Glove
- home-based occupational therapy
Conditions studied
- Brain Disorder — all drugs for Brain Disorder →
- Home Based Rehabilitation — all drugs for Home Based Rehabilitation →
Sponsor
Samsung Medical Center
Who can join
Adults 19 to 85, any sex, with Brain Disorder or Home Based Rehabilitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Glove by comparing the effects between a group using the home-based Neofect Smart Glove and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06837324
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Disorder
Currently open trials in the same condition.
- NCT06837363 — Effect of Untact Upper Extremity Rehabilitation Using a Smart Board for Late Subacute and Chronic Patients With Brain Di · NA · recruiting
- NCT05892510 — Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent · Phase 2, PHASE3 · recruiting
- NCT07397767 — Development of Quantitative Parameter of Upper Extremity Function in Patients With Brain Disorder Using Smart-Board and · NA · active not recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06837324 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06837324.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing